Abstract
MONARCH-2 trial assesed the efficacy and safety of abemaciclib in combination wth fulvestrant in patients with hormone-receptor positive metastatic breast cancer and endocrine resistant disease. MONARCH-2 trial proved both clinically and statistically significant improvement in PFS and ORR in abemaciclib arm with favourable safety profile.